Co-Diagnostics Inc
codiagnostics.comCo-Diagnostics Inc (NASDAQ: CODX) is a molecular diagnostics company that develops and sells polymerase chain reaction (PCR)-based diagnostic test kits and related platform instruments. Revenue comes from transactional sales of test kits, with a secondary hardware component in the Co-Dx Box and Co-Dx PCR point-of-care platform (the latter subject to FDA review and not available for sale as of the filing dated 2026-03-31). The company distributes through a global network of distributors covering clinical labs in more than 50 countries, per the FY2025 10-K. CODX positions itself as a low-cost provider of PCR diagnostics, citing proprietary and patented technology that the company states allows faster test design and lower manufacturing costs than some competitors. Products carry CE markings for several indications and are sold to municipalities, clinical laboratories, and public health agencies. The company is headquartered in Utah and was distributing its first products by 2019.
Products & Services
Logix Smart PCR test kits covering COVID-19 (single-gene and two-gene variants), a COVID-19 Direct Saliva extraction-free test, tuberculosis, Zika, Zika/dengue/chikungunya triplex, and ABC triplex (Flu A, Flu B, COVID-19). Vector Smart PCR tests for mosquito-borne pathogens including West Nile/western equine encephalitis/St. Louis encephalitis triplex, and a Zika/chikungunya/dengue triplex. Co-Dx Box point-of-care instrument. Co-Dx PCR platform (under FDA review as of 2026-03-31 filing, not available for sale).
Revenue Model
Transactional sales of PCR diagnostic test kits (Logix Smart and Vector Smart product lines) and diagnostic instruments (Co-Dx Box). Kits are sold through distributors to end-use laboratories and public health agencies. The company has also raised capital through at-the-market equity offerings, including a program with Maxim Group LLC allowing up to $10.0 million in share sales as of October 2025.
Customers & Markets
Clinical laboratories, public health agencies, and municipal mosquito abatement districts (more than 3,000 abatement districts exist throughout the United States per the FY2025 10-K). International customers served through distributors in more than 50 countries. End markets include infectious disease diagnostics, vector-borne disease surveillance, and point-of-care testing.
Geographic Exposure
United States (headquarters in Utah; primary domestic market including mosquito abatement districts). International sales through distributors covering clinical labs in more than 50 countries, with CE markings obtained for European Union market access (six tests CE-marked as of the FY2025 10-K filing).
Financial Snapshot
Loading...
